Volume 27, Number 2—February 2021
Research
Use of Commercial Claims Data for Evaluating Trends in Lyme Disease Diagnoses, United States, 2010–2018
Figure 1

Figure 1. Annual restricted and unrestricted MarketScan database enrollment population by year, United States, 2010–2018. The restricted MarketScan population was limited to enrollees with insurance coverage for an entire calendar year, with the potential for pharmaceutical claims data, and a primary beneficiary residing in the United States (excluding territories when possible).
Page created: December 10, 2020
Page updated: January 23, 2021
Page reviewed: January 23, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.